Alpha emitter radium-223 and survival in metastatic prostate cancer

C Parker; S Nilsson; D Heinrich; S I Helle; J M O'Sullivan; S D Fosså; A Chodacki; P Wiechno; J Logue; M Seke; A Widmark; D C Johannessen; P Hoskin; D Bottomley; N D James; A Solberg; I Syndikus; J Kliment; S Wedel; S Boehmer; M Dall'Oglio; L Franzén; R Coleman; N J Vogelzang; C G O'Bryan-Tear; K Staudacher; J Garcia-Vargas; M Shan; Ø S Bruland; O Sartor; ALSYMPCA Investigators

doi:10.1056/NEJMoa1213755

Alpha emitter radium-223 and survival in metastatic prostate cancer

C Parker
, S Nilsson
, D Heinrich
, S I Helle
, J M O'Sullivan
, S D Fosså
, A Chodacki
, P Wiechno
, J Logue
, M Seke
, A Widmark
, D C Johannessen
, P Hoskin
, D Bottomley
, N D James
, A Solberg
, I Syndikus
, J Kliment
, S Wedel
, S Boehmer

M Dall'Oglio, L Franzén, R Coleman, N J Vogelzang, C G O'Bryan-Tear, K Staudacher, J Garcia-Vargas, M Shan, Ø S Bruland, O Sartor, ALSYMPCA Investigators

Research output: Contribution to journal › Article › peer-review

3090 Citations (Scopus)

Abstract

Radium-223 dichloride (radium-223), an alpha emitter, selectively targets bone metastases with alpha particles. We assessed the efficacy and safety of radium-223 as compared with placebo, in addition to the best standard of care, in men with castration-resistant prostate cancer and bone metastases.

Original language	English
Pages (from-to)	213-23
Number of pages	11
Journal	New England Journal of Medicine
Volume	369
Issue number	3
DOIs	https://doi.org/10.1056/NEJMoa1213755
Publication status	Published - 18 Jul 2013

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Aged
Aged, 80 and over
Bone Neoplasms
Double-Blind Method
Humans
Isotopes
Kaplan-Meier Estimate
Male
Middle Aged
Prostatic Neoplasms
Radium

ASJC Scopus subject areas

General Medicine

Access to Document

10.1056/NEJMoa1213755

Cite this

Parker, C., Nilsson, S., Heinrich, D., Helle, S. I., O'Sullivan, J. M., Fosså, S. D., Chodacki, A., Wiechno, P., Logue, J., Seke, M., Widmark, A., Johannessen, D. C., Hoskin, P., Bottomley, D., James, N. D., Solberg, A., Syndikus, I., Kliment, J., Wedel, S., ... ALSYMPCA Investigators (2013). Alpha emitter radium-223 and survival in metastatic prostate cancer. New England Journal of Medicine, 369(3), 213-23. https://doi.org/10.1056/NEJMoa1213755

@article{6de340c0888344e1ab6b6ee6b57165b7,

title = "Alpha emitter radium-223 and survival in metastatic prostate cancer",

abstract = "Radium-223 dichloride (radium-223), an alpha emitter, selectively targets bone metastases with alpha particles. We assessed the efficacy and safety of radium-223 as compared with placebo, in addition to the best standard of care, in men with castration-resistant prostate cancer and bone metastases.",

keywords = "Aged, Aged, 80 and over, Bone Neoplasms, Double-Blind Method, Humans, Isotopes, Kaplan-Meier Estimate, Male, Middle Aged, Prostatic Neoplasms, Radium",

author = "C Parker and S Nilsson and D Heinrich and Helle, \{S I\} and O'Sullivan, \{J M\} and Foss{\aa}, \{S D\} and A Chodacki and P Wiechno and J Logue and M Seke and A Widmark and Johannessen, \{D C\} and P Hoskin and D Bottomley and James, \{N D\} and A Solberg and I Syndikus and J Kliment and S Wedel and S Boehmer and M Dall'Oglio and L Franz{\'e}n and R Coleman and Vogelzang, \{N J\} and O'Bryan-Tear, \{C G\} and K Staudacher and J Garcia-Vargas and M Shan and Bruland, \{{\O} S\} and O Sartor and \{ALSYMPCA Investigators\}",

year = "2013",

month = jul,

day = "18",

doi = "10.1056/NEJMoa1213755",

language = "English",

volume = "369",

pages = "213--23",

journal = "New England Journal of Medicine",

issn = "0028-4793",

publisher = "Massachussetts Medical Society",

number = "3",

}

Parker, C, Nilsson, S, Heinrich, D, Helle, SI, O'Sullivan, JM, Fosså, SD, Chodacki, A, Wiechno, P, Logue, J, Seke, M, Widmark, A, Johannessen, DC, Hoskin, P, Bottomley, D, James, ND, Solberg, A, Syndikus, I, Kliment, J, Wedel, S, Boehmer, S, Dall'Oglio, M, Franzén, L, Coleman, R, Vogelzang, NJ, O'Bryan-Tear, CG, Staudacher, K, Garcia-Vargas, J, Shan, M, Bruland, ØS, Sartor, O & ALSYMPCA Investigators 2013, 'Alpha emitter radium-223 and survival in metastatic prostate cancer', New England Journal of Medicine, vol. 369, no. 3, pp. 213-23. https://doi.org/10.1056/NEJMoa1213755

TY - JOUR

T1 - Alpha emitter radium-223 and survival in metastatic prostate cancer

AU - Parker, C

AU - Nilsson, S

AU - Heinrich, D

AU - Helle, S I

AU - O'Sullivan, J M

AU - Fosså, S D

AU - Chodacki, A

AU - Wiechno, P

AU - Logue, J

AU - Seke, M

AU - Widmark, A

AU - Johannessen, D C

AU - Hoskin, P

AU - Bottomley, D

AU - James, N D

AU - Solberg, A

AU - Syndikus, I

AU - Kliment, J

AU - Wedel, S

AU - Boehmer, S

AU - Dall'Oglio, M

AU - Franzén, L

AU - Coleman, R

AU - Vogelzang, N J

AU - O'Bryan-Tear, C G

AU - Staudacher, K

AU - Garcia-Vargas, J

AU - Shan, M

AU - Bruland, Ø S

AU - Sartor, O

AU - ALSYMPCA Investigators

PY - 2013/7/18

Y1 - 2013/7/18

N2 - Radium-223 dichloride (radium-223), an alpha emitter, selectively targets bone metastases with alpha particles. We assessed the efficacy and safety of radium-223 as compared with placebo, in addition to the best standard of care, in men with castration-resistant prostate cancer and bone metastases.

AB - Radium-223 dichloride (radium-223), an alpha emitter, selectively targets bone metastases with alpha particles. We assessed the efficacy and safety of radium-223 as compared with placebo, in addition to the best standard of care, in men with castration-resistant prostate cancer and bone metastases.

KW - Aged

KW - Aged, 80 and over

KW - Bone Neoplasms

KW - Double-Blind Method

KW - Humans

KW - Isotopes

KW - Kaplan-Meier Estimate

KW - Male

KW - Middle Aged

KW - Prostatic Neoplasms

KW - Radium

U2 - 10.1056/NEJMoa1213755

DO - 10.1056/NEJMoa1213755

M3 - Article

C2 - 23863050

SN - 0028-4793

VL - 369

SP - 213

EP - 223

JO - New England Journal of Medicine

JF - New England Journal of Medicine

IS - 3

ER -

Alpha emitter radium-223 and survival in metastatic prostate cancer

Abstract

UN SDGs

Keywords

ASJC Scopus subject areas

Access to Document

Fingerprint

Cite this